DEFINING AND VALIDATING BIOMARKERS OF RISK FOR PROGRESSIVE CERVICAL CANCER Release Date: January 9, 2002 NOTICE: NOT-CA-02-011 National Cancer Institute The Division of Cancer Epidemiology and Genetics (DCEG), Environmental Epidemiology Branch (EEB) of the National Cancer Institute is conducting a study to collect and store cervical tissue specimens that will be used for DNA and RNA analyses, in women representative of the four natural history categories in cervical neoplasia: normal, HPV- positive, precancer, and cancer. The main focus of the study is to identify and validate biomarkers at different stages of cervical neoplasia that may be predictive of disease. The proposed study will consist of two components: a cross-sectional component and a prospective component. The cross-sectional design will be used to identify candidate biomarkers of risk at each neoplastic stage. Based on the candidate markers generated from this analysis, their predictive value in progression and regression from HPV infection will be confirmed in the progressive design for the key intermediate outcomes: HPV clearance, HPV persistence, and progression to precancer. The entire study duration is planned for five years, we anticipate a 6- month start-up period, a 2-4 year recruitment of eligible women (2 years for normal and HPV-positive women, and up to 4 years to accrue adequate numbers of cancers and precancers), a 2-year follow-up period for HPV-positive women, and a 6-month close-out period. From each participant, a short interview will be conducted to assess known HPV co-factors, and biological specimens (blood, cervical secretions, cervical swabs) in addition to the biopsied cervix tissue will be collected. Intramural investigators at the National Cancer Institute (NCI) are implementing this effort to identify key biomarkers with potential prognostic value in cervical neoplasia. This work pertains to the implementation and conduct of the field effort to this study. It is anticipated that the Request For Proposal (RFP No. N02-CP-21005- 50) package will be available on or about January 15, 2002 with responses due within 30 calendar days following the actual date of issuance of the RFP. The RFP may be accessed via the NCI Research Contracts Branch (RCB) website: http://rcb.nci.nih.gov/ under "Current Requests For Proposals". Award of this project is anticipated by June 30, 2002. INQUIRIES For further information, contact: Karen L. McFarlane Contracting Officer Epidemiology and Support Section, RCB Executive Plaza South 6120 Executive Boulevard Rockville, MD 20892-7224 email: km63k@nih.gov Voice: (301) 435-3782 Fax: (301) 480-0241
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |